publication date: Oct. 26, 2018

Clinical Roundup Keytruda improved OS as monotherapy and in combination with chemo in first-line recurrent or metastatic head and neck cancer

Merck announced the first presentation of interim data from the pivotal phase III KEYNOTE-048 trial investigating Keytruda as both monotherapy and in combination with chemotherapy for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.

Interim data from KEYNOTE-048 showed Keytruda monotherapy improved overall survival, a primary endpoint of the study, by 39 percent (HR 0.61 [95% CI, 0.45-0.83]; p=0.0007) in patients whose tumors expressed PD-L1 with Combined Positive Score≥20, and by 22 percent (HR 0.78 [95% CI, 0.64-0.96]; p=0.0086) in patients with CPS≥1, compared to the EXTREME regimen (cetuximab with carboplatin or cisplatin plus 5-fluorouracil), the current standard of care.

In addition, Keytruda in combination with chemotherapy (carboplatin or cisplatin plus 5-FU) (Keytruda combination) demonstrated improved OS compared to the EXTREME regimen by 23 percent (HR 0.77 [95% CI, 0.63-0.93]; p=0.0034), regardless of PD-L1 expression. At the final analysis, superiority for OS will be evaluated for Keytruda monotherapy in the total population and Keytruda combination in patients whose tumors express PD-L1 at CPS≥20 and CPS≥1; at this interim analysis, based upon the prespecified testing algorithm, non-inferiority for Keytruda monotherapy in the total population was demonstrated and statistical significance was not achieved for the Keytruda combination … Continue reading Keytruda improved OS as monotherapy and in combination with chemo in first-line recurrent or metastatic head and neck cancer

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.